Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

β-Sheet Structure within the Extracellular Domain of C99 Regulates Amyloidogenic Processing.

Hu Y, Kienlen-Campard P, Tang TC, Perrin F, Opsomer R, Decock M, Pan X, Octave JN, Constantinescu SN, Smith SO.

Sci Rep. 2017 Dec 7;7(1):17159. doi: 10.1038/s41598-017-17144-0.

2.

Alzheimer's Disease: From Genetic Variants to the Distinct Pathological Mechanisms.

Sun Q, Xie N, Tang B, Li R, Shen Y.

Front Mol Neurosci. 2017 Oct 6;10:319. doi: 10.3389/fnmol.2017.00319. eCollection 2017. Review.

3.

Identification of key regions and residues controlling Aβ folding and assembly.

Hayden EY, Hoi KK, Lopez J, Inayathullah M, Condron MM, Teplow DB.

Sci Rep. 2017 Oct 3;7(1):12434. doi: 10.1038/s41598-017-10845-6.

4.

Influence of mismatched and bulged nucleotides on SNP-preferential RNase H cleavage of RNA-antisense gapmer heteroduplexes.

Magner D, Biala E, Lisowiec-Wachnicka J, Kierzek R.

Sci Rep. 2017 Oct 2;7(1):12532. doi: 10.1038/s41598-017-12844-z.

5.

Molecular Origins of the Compatibility between Glycosaminoglycans and Aβ40 Amyloid Fibrils.

Stewart KL, Hughes E, Yates EA, Middleton DA, Radford SE.

J Mol Biol. 2017 Aug 4;429(16):2449-2462. doi: 10.1016/j.jmb.2017.07.003. Epub 2017 Jul 10.

6.

The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease.

MacLeod R, Hillert EK, Cameron RT, Baillie GS.

Future Sci OA. 2015 Nov 1;1(3):FSO11. doi: 10.4155/fso.15.9. eCollection 2015 Nov. Review.

7.

Structural Polymorphism of Alzheimer's β-Amyloid Fibrils as Controlled by an E22 Switch: A Solid-State NMR Study.

Elkins MR, Wang T, Nick M, Jo H, Lemmin T, Prusiner SB, DeGrado WF, Stöhr J, Hong M.

J Am Chem Soc. 2016 Aug 10;138(31):9840-52. doi: 10.1021/jacs.6b03715. Epub 2016 Jul 28.

8.

Genes associated with Alzheimer's disease: an overview and current status.

Giri M, Zhang M, Lü Y.

Clin Interv Aging. 2016 May 17;11:665-81. doi: 10.2147/CIA.S105769. eCollection 2016. Review.

9.

High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide.

Rauth S, Hinz D, Börger M, Uhrig M, Mayhaus M, Riemenschneider M, Skerra A.

Biochem J. 2016 Jun 1;473(11):1563-78. doi: 10.1042/BCJ20160114. Epub 2016 Mar 30.

10.

A Tandem Oligonucleotide Approach for SNP-Selective RNA Degradation Using Modified Antisense Oligonucleotides.

Magner D, Biala E, Lisowiec-Wachnicka J, Kierzek E, Kierzek R.

PLoS One. 2015 Nov 6;10(11):e0142139. doi: 10.1371/journal.pone.0142139. eCollection 2015. Erratum in: PLoS One. 2016;11(9):e0163575.

11.

The influence of the amyloid ß-protein and its precursor in modulating cerebral hemostasis.

Van Nostrand WE.

Biochim Biophys Acta. 2016 May;1862(5):1018-26. doi: 10.1016/j.bbadis.2015.10.020. Epub 2015 Oct 27. Review.

12.

Analysis by a highly sensitive split luciferase assay of the regions involved in APP dimerization and its impact on processing.

Decock M, El Haylani L, Stanga S, Dewachter I, Octave JN, Smith SO, Constantinescu SN, Kienlen-Campard P.

FEBS Open Bio. 2015 Sep 6;5:763-73. doi: 10.1016/j.fob.2015.09.002. eCollection 2015.

13.

Amyloid β-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation.

Zheng X, Liu D, Roychaudhuri R, Teplow DB, Bowers MT.

ACS Chem Neurosci. 2015 Oct 21;6(10):1732-40. doi: 10.1021/acschemneuro.5b00171. Epub 2015 Aug 12.

14.

Two distinct β-sheet structures in Italian-mutant amyloid-beta fibrils: a potential link to different clinical phenotypes.

Hubin E, Deroo S, Schierle GK, Kaminski C, Serpell L, Subramaniam V, van Nuland N, Broersen K, Raussens V, Sarroukh R.

Cell Mol Life Sci. 2015 Dec;72(24):4899-913. doi: 10.1007/s00018-015-1983-2. Epub 2015 Jul 21.

15.

The Maze of APP Processing in Alzheimer's Disease: Where Did We Go Wrong in Reasoning?

Chen M.

Front Cell Neurosci. 2015 May 28;9:186. doi: 10.3389/fncel.2015.00186. eCollection 2015. Review.

16.

Alternative salt bridge formation in Aβ-a hallmark of early-onset Alzheimer's disease?

Schledorn M, Meier BH, Böckmann A.

Front Mol Biosci. 2015 Apr 28;2:14. doi: 10.3389/fmolb.2015.00014. eCollection 2015.

17.

Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice.

Yuzwa SA, Shan X, Jones BA, Zhao G, Woodward ML, Li X, Zhu Y, McEachern EJ, Silverman MA, Watson NV, Gong CX, Vocadlo DJ.

Mol Neurodegener. 2014 Oct 26;9:42. doi: 10.1186/1750-1326-9-42.

18.

Genetic heterogeneity in Alzheimer disease and implications for treatment strategies.

Ringman JM, Goate A, Masters CL, Cairns NJ, Danek A, Graff-Radford N, Ghetti B, Morris JC; Dominantly Inherited Alzheimer Network.

Curr Neurol Neurosci Rep. 2014 Nov;14(11):499. doi: 10.1007/s11910-014-0499-8. Review.

19.

Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients.

Watts JC, Condello C, Stöhr J, Oehler A, Lee J, DeArmond SJ, Lannfelt L, Ingelsson M, Giles K, Prusiner SB.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10323-8. doi: 10.1073/pnas.1408900111. Epub 2014 Jun 30.

20.

Clinical genetics of Alzheimer's disease.

Zou Z, Liu C, Che C, Huang H.

Biomed Res Int. 2014;2014:291862. doi: 10.1155/2014/291862. Epub 2014 May 13. Review.

Supplemental Content

Support Center